PROACT - Pre-Operative Arimidex Compared To Tamoxifen
Study identifier:1033IL/0039
ClinicalTrials.gov identifier:N/A
EudraCT identifier:N/A
CTIS identifier:N/A
Study Complete
Official Title
A randomised, double-blind, study comparing ARIMIDEX™ with NOLVADEX™ as neo-adjuvant and adjuvant treatment in post-menopausal women with large operable (T2 (≥3cm), T3, N0-2, M0) or potentially-operable, locally advanced (T4b, N0-2, M0), ER+ and/or PR+ breast cancer.
Medical condition
Breast Cancer
Phase
Phase 3
Healthy volunteers
No
Study drug
ARIMIDEX (anastrazole), NOLVADEX (tamoxifen)
Sex
Female
Actual Enrollment
452
Study type
Interventional
Age
60 Years +
Date
Study Start Date: 01 Aug 2000
Primary Completion Date: 01 Jan 2003
Study Completion Date: 01 Dec 2007
Study design
Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind
Primary Purpose: Treatment
Verification:
Verified 01 Dec 2013 by AstraZeneca Pharmaceuticals
Sponsors
AstraZeneca Pharmaceuticals
Collaborators
-
Inclusion and exclusion criteria
Loading...
No locations available
| Arms | Assigned Interventions |
|---|
Contacts
Investigators
Principal Investigator
AstraZeneca Arimidex Medical Science Director
AstraZeneca
